BARDA Awards $375 million to develop COVID-19 pre-exposure prophylaxis
On Jan. 16, 2025, Shionogi Inc. has been awarded a $375 million project agreement through the Rapid Response…
-
-
Study maps bed bugs’ genomes in unprecedented detail to find out why they won’t die
On Dec. 17, 2024, scientists from Hiroshima University announced they had mapped near-gap-free and near-error-free genomes of a…
-
Biotechnology | COVID-19 | HIV | Vaccine
WHO added LC16m8 mpox vaccine to Emergency Use Listing
On Nov. 19, 2024, the World Health Organization (WHO) announced it had granted Emergency Use Listing (EUL) to Japan-based…
-
Recent COVID-19 vaccination tied to lower risk of long COVID
On Nov. 6, 2024, data from the VENUS (Vaccine Effectiveness, Networking, and Universal Safety) study in Japan revealed…
-
living microbes discovered in 2-billion-year-old rock in South Africa
On Oct. 2, 2024, a team of researchers from the University of Tokyo announced they had discovered living…
-
Japan’s MHLW Approved CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
On Sept. 13, 2024, CSL Seqirus and sa-mRNA pioneer Arcturus Therapeutics announced that Japan’s Ministry of Health, Labor…
-
scientist-run Pathoplexus virus database vows to be transparently run and simple to use
On Aug. 29, 2024, a small team of scientists has launched an open-source database for some of the…
-
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrated Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
On Feb. 5, 2024, CSL and and Arcturus Therapeutics announced the results of a follow-up analysis of a…
-
The CDC opened new East Asia and Pacific Regional Office in Japan
On Feb. 5, 2024, a U.S. Centers for Disease Control and Prevention (CDC) celebrated the opening of the…
-
CCSL and Arcturus Therapeutics’ ARCT-154 Demonstrated Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
On Dec. 21, 2023, CSL and and Arcturus Therapeutics announced the results of a Phase 3 study showing…
-
Japan’s MHLW approved CSL and Arcturus’s self-amplifying mRNA vaccine approved for COVID in adults
On Nov. 28, 2023, CSL and Arcturus Therapeutics announced that Japan’s Ministry of Health, Labor and Welfare (MHLW)…
-
The Pearl Oyster genome was sequenced
On Nov. 10, 2022, researchers from the Okinawa Institute of Science and Technology (OIST), in collaboration with K….
-
Japan approved partial change to a NDA for Omicron-targeting bivalent booster COVID-19 vaccine
On Oct. 31, 2022, Moderna announced that it had received approval from the Ministry of Health, Labour and…
-
Japanese vaccine database Created to assess Vaccine Effectiveness and adverse events
On Oct. 6, 2022, researchers in Japan released a study that described the development and application of the…
-
Washington University in St. Louis COVID-19 nasal vaccine technology licensed to Ocugen
On Oct. 4, 2022, Washington University in St. Louis announced it had licensed the rights to develop, manufacture…
-
Merck and Ridgeback announced supply agreement with UNICEF for molnupiravir, investigational oral antiviral COVID-19 medicine
On Jan. 18, 2022, Merck and Ridgeback Biotherapeutics announced the signing of a long-term supply agreement with the…
-
Merck and Ridgeback’s molnupiravir, an investigational oral antiviral COVID-19 treatment, received special approval for emergency in Japan
On Dec. 24, 2021, Merck and Ridgeback Biotherapeutics announced that Japanﾒs Ministry of Health, Labor and Welfare had…
-
Novavax announced submission of New Drug Application in Japan for approval of COVID-19 vaccine
On Dec. 15, 2021, Novavax announced the submission of a New Drug Application to the Ministry of Health,…
-
Takeda announced manufacture and provision of 150 million doses of Novavax COVID-19 vaccine candidate to the government of Japan
On Sept. 7, 2021, Takeda Pharmaceutical announced the Government of Japan’s Ministry of Health, Labour and Welfare purchase…
-
FDA authorized new high-throughput, automated system for leading COVID-19 test
On Apr. 12, 2021, Thermo Fisher Scientific announced that the U.S. Food and Drug Administration (FDA) had granted…
-
Antiviral drug Favipiravir investigated as a possible COVID-19 treatment for at-home recovery in PRINCIPLE trial
On Apr. 8, 2021, Oxford University announced that favipiravir was to be investigated in the UK as part…
-
Novavax and Takeda finalized license agreement for Novavax COVID-19 vaccine candidate in Japan
On Feb. 26, 2021, Novavax and Takeda Pharmaceutical announced an exclusive license agreement for Takeda’s development, manufacturing and…
-
G7 leaders committed US$ 4.3 billion to finance global equitable access to tests, treatments and vaccines
On Feb. 19, 2021, the ACT Accelerator partnership welcomed over US$ 4.3 billion of new investments from the…
-
Oxford Immunotec signed distributor agreement with RIKEN Genesis for T-SPOT Discovery SARS-CoV-2 Kit in Japan
On Dec. 2, 2020, Oxford Immunotec announces an exclusive distribution agreement with RIKEN Genesis in Japan. Under the…
-
Early mutation in SARS-CoV-2 virus in Europe led to its domination world wide
On Nov. 12, 2020, a study published in Science by a team of researchers in the U.S. and…
-
Moderna partnered with Takeda and Government of Japan to supply 50 million doses of mRNA vaccine against COVID-19
On Oct. 29, 2020, Takeda Pharmaceutical announced that it would import and distribute 50 million doses of Moderna’s…
-
Global clinical trials of COVID-19 vaccine resumed
On Oct. 23, 2020, the U.S. FDA authorised a restart of clinical trials of the ChAdOx1 nCov-2019 Oxford…
-
FDA authorised restart of the COVID-19 AZD1222 vaccine US phase III trial
On Oct. 23, 2020, AstraZeneca announced that the clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, had…
-
WHO announced position on genetically modified mosquitoes
On Oct. 14, 2020, recognizing the urgent need for new tools to combat vector-borne diseases (VBDs), and in…
-
COVID-19 vaccine AZD1222 clinical trial resumed in Japan, follows restart of trials in the UK, Brazil, South Africa and India
On Oct. 2, 2020, AstraZeneca announced the phase I/II clinical trial for the COVID-19 vaccine AZD1222 had resumed…
